Stanford Medicine has moved cell therapy for blood cancer out of the lab and into the clinic, giving the first commercial dose of Orca-T to a patient. This marks the first time the therapy is available outside of trials, after years of research and development.
TREGZI is engineered to include not only regulatory T cells but also hematopoietic stem and progenitor cells, allowing for precise control of cell populations in the graft rather than relying on the heterogeneous mixtures used in standard transplants.
Orca-T, created by Stanford scientists, takes aim at one of the biggest dangers in donor stem cell transplants: graft-versus-host disease (GVHD). In standard transplants, donor immune cells can attack the patient’s healthy tissues, sometimes with severe results. Orca-T changes the mix by adding regulatory T (Treg) cells to the graft, shielding healthy tissue while still fighting cancer.
Engineering the transplant to outsmart GVHD
Standard donor stem cell transplants use a single infusion of a mixed batch of donor stem cells, mature immune cells, and early blood cells. This can rebuild the immune system and fight cancer, but it often sparks GVHD, a complication that has limited how widely transplants are used. The main challenge is to stop GVHD without weakening the graft’s power to kill cancer.
After approval, TREGZI was discussed as available in clinical practice for hematologic malignancy transplants, with OncLive highlighting its use in myeloablative regimens and the potential to avoid post-transplant cyclophosphamide in favor of tacrolimus alone.
David Miklos, MD, PhD, who leads Stanford’s Blood Marrow Transplantation and Cellular Therapy Division, credits the therapy’s engineered approach for lowering transplant toxicity. He sees a future where grafts are further tuned with targeted immune cells to stop cancer from coming back.
First patient treated and ongoing research
Lori Muffly, MD, professor at Stanford Cancer Institute, treated the first commercial Orca-T patient, who has high-risk leukemia. The patient chose Orca-T for its lower chemotherapy needs and fewer side effects. Muffly put it plainly: “Our goal is to cure him without significant side effects from transplant and help him get back to his life, family, and job over the coming months.”
Unlike the single, unrefined cell mix in standard transplants, Orca-T uses several infusions: stem and early blood cells first, then Treg cells, and finally mature immune cells. Muffly compares it to following a recipe, with the right balance set before the transplant instead of relying on chemotherapy after. Even as Orca-T becomes part of routine care, Stanford is still studying how it works in different groups and with other treatments. Recent trials have looked at its use in older patients and in cases where matched donors are hard to find—a key issue for patients from underrepresented backgrounds.
Targeted Oncology reports that TREGZI is approved for at least acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes in matched donor transplants as reported by Targeted Oncology.
Stanford’s commitment to Orca-T runs deep. Muffly, who has worked on its clinical trials for over a decade, called the move from lab to clinic “a really exciting thing to experience.” The sense of progress is clear, but so is the push to keep improving outcomes.
Implications for cell therapy and the future of transplantation
Orca-T’s FDA approval signals a new era for engineered cell therapies in blood cancer. By showing that careful cell engineering can sharply cut GVHD without losing effectiveness, Stanford has set a new bar for the field. The next round of research is already underway, testing how far this approach can go, including adding CAR-T cells and using the therapy for patients without matched donors.
For those watching cell therapy’s evolution, this step echoes the momentum seen in other advanced immunotherapies, as reported earlier in pancreatic cancer. What stands out here is the precision: the immune system is being rebuilt at the cellular level, not just to fight cancer but to protect patients from the risks of transplantation itself.
Stanford’s work shows that the era of rough, one-size-fits-all transplants is fading. The future of cell therapy will be shaped by engineered precision, proven protocols, and a focus on patient quality of life. Orca-T’s launch is a milestone, but it also raises the bar for the rest of the field to deliver not just survival, but a better life after treatment.
